<DOC>
	<DOC>NCT01831531</DOC>
	<brief_summary>This trial aims to study the safety, the local control, and the overall survival of S-1 combined with radiotherapy for patients with esophageal squamous cell carcinoma. 105 patients will be recruited into this trial.</brief_summary>
	<brief_title>Study of S-1 in Combination With Radiotherapy in Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Joined the study voluntarily and signed informed consent form; Age ＞75 or age 1875 who are intolerant of or reject intravenous chemotherapy Both genders Esophageal squamous cell carcinoma confirmed by pathology Local advanced esophageal squamous cell carcinoma (T24N01M01a,TxN1M01a,TxNxM1a, AJCC 6th) No radiotherapy, chemotherapy or other treatments prior to enrollment PS ECOG 02 Life expectancy of more than 3 months Hemoglobin（Hb）≥9 g/dL WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L platelet count (Pt) ≥100x 109/L Hepatic function: ALAT and ASAT &lt; 2.5 x ULN, TBIL&lt;1.5 x ULN Renal function: creatinine &lt; 1.5 x ULN No immunodeficiency Use of an effective contraceptive for adults to prevent pregnancy. Complete esophageal obstruction Deep esophageal ulcer Esophageal perforation Haematemesis After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting therapy Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years Participation in other interventional clinical trials within 30 days Pregnant or breastfeeding women or people during the birthperiod who refused to take contraceptives Drug addiction Alcoholism or AIDS Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior Patient who has metastasis such as lung, liver metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>